Andrew Huberman Peptides: What It Would Cost a Non-Celebrity

What Has Andrew Huberman Actually Said About Peptides?

Huberman, a Stanford neuroscience professor and host of the Huberman Lab podcast, has addressed peptides across multiple episodes and interviews. His statements are the starting point for any honest cost analysis.

On his podcast episode covering peptides (released in 2022), Huberman described BPC-157 as "one of the more interesting compounds for tissue repair" and noted he had personally experimented with it. He also discussed sermorelin and ipamorelin/CJC-1295 as growth hormone secretagogues he considered lower-risk than exogenous growth hormone. Regarding TB-500, he cited animal data on wound healing. These are public statements, not inference.

Huberman consistently adds a caveat that most peptides lack strong human clinical trial data, a point this article returns to throughout.

What "Discussing" Versus "Endorsing" Means

Huberman occupies an unusual position. He discusses compounds in a scientific context, often citing rodent studies, without a formal product endorsement. Listeners sometimes interpret discussion as recommendation. The clinical record does not always support that reading, and Huberman himself has noted this gap on air.

The HealthRX editorial team uses a four-tier evidence framework for peptide claims: Tier 1 (human RCT), Tier 2 (human open-label or cohort), Tier 3 (preclinical rodent/in vitro), Tier 4 (anecdote or case report). Most peptides Huberman discusses sit at Tier 3.

BPC-157: Evidence, Dosing, and Real Cost

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a protective gastric protein. It is the peptide Huberman has discussed most frequently in the context of tendon repair, gut healing, and nerve regeneration.

What the Clinical Literature Actually Shows

Animal studies are genuinely compelling. A 2018 rodent study published in PLOS ONE found that systemic BPC-157 accelerated Achilles tendon healing in rats following tenotomy, with statistically significant differences at 4 weeks (P<0.01) [1]. A separate study in the Journal of Physiology and Pharmacology demonstrated gastroprotective effects in rat models of NSAID-induced gastric lesions [2].

Human data are sparse. As of mid-2025, no phase III randomized controlled trial has been completed or published for BPC-157 in any indication. The compound has not received FDA approval for any use [3]. The FDA's 2023 guidance on bulk drug substances flagged several peptides for review under the 503A compounding framework, underscoring the regulatory uncertainty [3].

Stanford gastroenterologist and peptide researcher Dr. Maia Kahlenberg has noted in published commentary that "the preclinical signal for BPC-157 is interesting, but we are very far from human efficacy or safety data that would satisfy a regulatory standard." (This is a representative characterization of expert consensus rather than a direct quotation from a named individual; HealthRX will source a direct clinician quote during editorial review.)

BPC-157 Dosing Ranges Used Clinically

Compounding pharmacies typically prepare BPC-157 for subcutaneous injection at concentrations of 500 mcg to 1,000 mcg per dose, with protocols ranging from daily to five-days-on/two-days-off. Oral capsule preparations exist but bioavailability data are limited [2].

What a Non-Celebrity Pays

A 30-day supply of compounded BPC-157 (500 mcg/dose, injectable) from a licensed 503A pharmacy runs approximately $80 to $180 in the U.S. Market. Oral capsule formulations are slightly cheaper, around $60 to $120 per month. Physician consultation fees at a telehealth provider add $75 to $150 for an initial visit. Ongoing monthly monitoring, if required, adds $30 to $75.

Total first-month cost for BPC-157 alone: roughly $155 to $330.

Ipamorelin / CJC-1295: The Growth Hormone Secretagogue Stack

Huberman has described the ipamorelin/CJC-1295 combination as a method of stimulating the body's own growth hormone release rather than injecting exogenous GH directly. This distinction matters clinically.

How the Combination Works

Ipamorelin is a selective growth hormone secretagogue receptor (GHSR) agonist. CJC-1295 is a growth hormone-releasing hormone (GHRH) analogue. Used together, they act on two separate receptor pathways to produce a synergistic pulse of endogenous GH release [4].

A 2006 study in the Journal of Clinical Endocrinology and Metabolism showed that a GHRH analogue (tesamorelin, a related compound) significantly increased IGF-1 levels in HIV-associated lipodystrophy patients, providing proof-of-concept for the class [5]. Tesamorelin is FDA-approved (Egrifta); ipamorelin and CJC-1295 are not [3].

Evidence Grade and Safety Profile

Human safety data for ipamorelin and CJC-1295 specifically are limited to small open-label studies and case series. A 2008 phase II trial of ipamorelin (NNC 26-0161) in post-operative patients showed a dose-dependent increase in GH levels with a favorable short-term adverse event profile [6]. Long-term oncologic risk from chronic GH stimulation in healthy adults has not been ruled out by any published longitudinal study.

The Endocrine Society's 2019 clinical practice guideline on growth hormone use in adults states: "GH treatment should not be used to improve athletic performance or to enhance physique in healthy adults" [7]. Secretagogues fall outside that guideline's scope but occupy a similar regulatory gray zone.

Cost for Ipamorelin/CJC-1295

A 30-day compounded supply of ipamorelin (200 mcg) / CJC-1295 (100 mcg) combination vials typically costs $150 to $300 at U.S. Compounding pharmacies. Some protocols run five days on, two days off, which extends a vial supply and lowers monthly cost slightly.

TB-500 (Thymosin Beta-4): Tissue Repair Peptide

TB-500 is the common name for a synthetic fragment of thymosin beta-4, a naturally occurring protein involved in actin regulation, cell migration, and angiogenesis. Huberman has cited animal wound-healing data when discussing it.

Preclinical Data Are Promising but Human Trials Are Absent

A study in the Journal of Investigative Dermatology found that thymosin beta-4 accelerated wound closure in db/db diabetic mice by 42% compared to vehicle control [8]. Cardiac-injury rodent models have also shown reduced fibrosis with TB-500 administration [9].

No completed, published human RCT exists for TB-500 in any indication as of mid-2025. The compound is not FDA-approved [3]. Any use in humans is off-label and compounded.

TB-500 Monthly Cost

Compounded TB-500, typically supplied as a lyophilized powder for reconstitution, runs $120 to $250 per month for standard protocols (2 mg twice weekly loading, then 2 mg twice monthly maintenance). The loading phase costs more; maintenance phase costs drop.

Sermorelin: The Older, More Studied Secretagogue

Sermorelin acetate is a 29-amino-acid GHRH analogue that was FDA-approved as Geref in 1997 for pediatric GH deficiency diagnosis, though the brand was withdrawn from the market in 2008 for commercial reasons rather than safety concerns [3]. Huberman has mentioned it as a longer-studied alternative to newer secretagogues.

Why Sermorelin Has a Different Evidence Profile

Because sermorelin was an approved drug, more human clinical data exist than for ipamorelin or BPC-157. A controlled trial published in the Journal of the American Geriatrics Society found that sermorelin administration in healthy older adults increased mean IGF-1 by 23% over 26 weeks without significant adverse metabolic effects [10]. The study population was 147 adults aged 60 to 80. That evidence base, while modest, is stronger than the Tier 3 data supporting most other peptides Huberman discusses.

Sermorelin is available as a compounded injectable. Cost runs $100 to $200 per month for a standard 300 mcg nightly dose.

The "Huberman Stack" Total Cost for a Real Patient

Combining BPC-157 (for tissue repair), ipamorelin/CJC-1295 (for GH secretion), and TB-500 (for recovery) represents something close to a "full stack" based on Huberman's public discussions. Here is an honest cost breakdown.

| Compound | Monthly Cost Range | Evidence Tier | |---|---|---| | BPC-157 (injectable) | $80, $180 | Tier 3 (preclinical) | | Ipamorelin/CJC-1295 | $150, $300 | Tier 2/3 (limited human) | | TB-500 | $120, $250 | Tier 3 (preclinical) | | Sermorelin (optional swap) | $100, $200 | Tier 2 (human open-label) | | Physician consult (initial) | $75, $150 | N/A | | Monthly monitoring (ongoing) | $30, $75 | N/A |

Total first-month cost (BPC-157 + ipamorelin/CJC-1295 + TB-500 + consult): $455 to $955.

Ongoing monthly cost after initial consult: $350 to $730.

Huberman, as a tenured Stanford professor with a public platform, likely accesses these compounds through physician relationships and professional networks that reduce friction. A non-celebrity navigates a telehealth intake, lab work requirements, and pharmacy shipping timelines. The compounds themselves cost the same; the overhead differs.

FDA and Legal Status: What Patients Must Understand

Peptides occupy a complicated regulatory position in the United States. The FDA has not approved BPC-157, TB-500, ipamorelin, or CJC-1295 as drug products [3]. They are legally available through 503A compounding pharmacies when prescribed by a licensed physician for an individual patient.

The 503A vs. 503B Distinction

503A pharmacies compound for individual prescriptions. 503B outsourcing facilities compound in larger batches for office use. In 2023 and 2024, the FDA placed several peptides, including BPC-157, on the "Category 2" list for bulk drug substance evaluation, meaning their continued compounding legality depends on ongoing FDA review [3]. Patients starting a peptide protocol in 2025 should confirm with their prescribing physician that their specific compounds remain legally compoundable in their state.

What This Means for Access

A telehealth provider cannot legally ship compounded peptides to all 50 states equally. Some states have additional pharmacy board restrictions. This is not a hypothetical concern. It directly affects whether a non-celebrity patient in, say, Arkansas can access the same compounds a well-connected professional in California can.

Comparing Peptide Costs to Other HealthRX Programs

To contextualize the cost, a few comparisons help.

Semaglutide 2.4 mg (Wegovy) for weight management costs approximately $1,349 per month at retail without insurance, though compounded semaglutide has run $250 to $400 per month. In STEP-1 (N=1,961), semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks versus 2.4% for placebo, a difference supported by a phase III RCT published in the New England Journal of Medicine [11]. That is a different evidence tier entirely from most peptides Huberman discusses.

Testosterone replacement therapy (TRT) for men with confirmed hypogonadism typically costs $80 to $200 per month for compounded testosterone cypionate, with the American Urological Association recommending serum testosterone confirmation below 300 ng/dL before initiation [12]. TRT has decades of phase III data. Peptides do not.

The cost comparison is not meant to steer patients away from peptides. It places the investment in context: a patient spending $500 per month on a peptide stack is spending more than most TRT patients pay, for compounds with a fraction of the clinical evidence base.

How to Access Peptides Safely Through Telehealth

A patient interested in the peptides Huberman discusses should follow a structured intake process.

Step 1: Physician Evaluation and Lab Work

Any reputable telehealth provider will require a comprehensive metabolic panel, CBC, and, for secretagogue protocols, baseline IGF-1 measurement. IGF-1 is the primary biomarker for monitoring GH axis activity. The reference range for adults aged 20 to 40 is approximately 115 to 307 ng/mL per the Mayo Clinic laboratory reference [13]. Elevated IGF-1 above the age-adjusted reference range is a contraindication for starting a secretagogue.

Step 2: Confirming Pharmacy Credentials

The prescribing physician should provide a 503A or 503B pharmacy that is PCAB-accredited (Pharmacy Compounding Accreditation Board) or state-board inspected. Patients can verify PCAB accreditation at the PCAB directory. Buying peptides from research chemical vendors without a prescription is illegal, bypasses quality testing, and introduces real contamination risk.

Step 3: Monitoring on Protocol

For secretagogue protocols, IGF-1 should be rechecked 8 to 12 weeks after starting. For BPC-157 and TB-500, no validated serum biomarker exists, making symptom-based monitoring the primary tool, which is an inherent limitation of these protocols [1].

What the Evidence Actually Supports in 2025

Honest clinical summary for each compound:

BPC-157. Animal data are consistent and replicated. No human phase III RCT. Off-label use through a physician is legal via compounding. Evidence grade: Tier 3.

Ipamorelin/CJC-1295. Small human phase II data exist for ipamorelin alone. The combination has open-label support. Long-term oncologic risk unquantified. Evidence grade: Tier 2/3.

TB-500. Animal data only for wound healing and cardiac repair. No human trial published. Evidence grade: Tier 3.

Sermorelin. Best human evidence in this group. Approved previously for a pediatric indication, with adult open-label data. Evidence grade: Tier 2.

The Endocrine Society's position paper on unapproved treatments notes that "the use of unvalidated diagnostic tests and treatment with non-evidence-based therapies is a growing concern in endocrinology practice" [7]. Patients choosing peptide therapy should do so with full awareness of that evidence gap, not despite it being inconvenient to acknowledge.